Correction to The protecT trial: What can we expect? [Lancet Oncol (2014), 15, 1046-47]
The Lancet Oncology , Volume 15 - Issue 11 p. e475
In this Comment, the last sentence in the second-tolast paragraph should have stated “… the 10-year prostate cancer survival
reported by active surveillance cohorts, with more similar tumour characteristics, ranges from 96–100%”.
This correction has been made to the online version as of Sept 29, 2014.
|The Lancet Oncology|
|Organisation||Department of Urology|
Roobol-Bouts, M.J, & Bokhorst, L.P. (2014). Correction to The protecT trial: What can we expect? [Lancet Oncol (2014), 15, 1046-47]. The Lancet Oncology, 15(11). doi:10.1016/S1470-2045(14)70503-0